Member Info for inanaco

Goes of on one .... re-post this ... Agema Historical Posts ""The market took advantage of a 31% discount. What idiot would not. A no brainier."" Discounts to sp�s are nearly always took up. It�s always virtually an instant profit. What fund would turn that down.! Agema's Folly Circa 23rd of April 2018 ... Thus Agema agrees this price is cheap and Scancell is a buy at this level.

Happy birthday ..

anyway your just waffling ... so leave you with it

what ??? this are your words .... not mine """However it is often these shares which rise and fall most quickly.It is Market Cap which is a better indicator of progress rather than SP unless you are a trader.""" i guess you have just researched MCAP ...

Nobody is buying and selling on Points of view, the problem with generalisation when you don't have a "poll" or a vote, it becomes your personal assumption which is always biased to how you think .. and then your trying to think for others ... every one is a individual as such buy sell or hold is personal, and that applies to risk and reward also ... what bugs me is when so called experts generalise Scancell ... well other shares did that so Scancell might .... that sort of statement is a bad reflection of the writers inability to quantify Scancell ... so has to Generalise Big Pharma have pipelines in development ...... or have you not understood my posts ... ?

Ivy """However it is often these shares which rise and fall most quickly.It is Market Cap which is a better indicator of progress rather than SP unless you are a trader.""" explain what market Cap is ... ? and does it change with the SP

Its done now, so you can think about "effect" of that cash on the SP ... rather than the "effect" of no cash ...

Exactly what the cash is for The net proceeds from the Capital Raise, in addition to the Company's existing cash resources and anticipated tax credits, will be used to: � Commence the SCIB1-checkpoint inhibitor Phase 2 US combination study in late stage melanoma, planned to start in Q4 2018 (subject to FDA approval) utilising the Ichor TriGrid v2.0 electroporation device; � Support the Cancer Research UK ("CRUK") development of SCIB2 for non-small-cell lung cancer ("NSCLC"); � Commence the First-In-Human study with Modi-1 in patients with triple-negative breast cancer ("TNBC"), ovarian cancer and sarcoma planned to start in H1 2019; � Identify Modi-specific T cell receptors in collaboration with BioNTech; and � Initiate pre-clinical Modi-2 development programme for oesophageal, gastric, pancreatic and colorectal cancers. so no need to raise any funds for at least 18 months, as the major costs of the trials is an ongoing cost already covered

you can only estimate as cost of modi1 is unknown.

Glued to the screens ... LOL

to the wider market, calling Buy and Hold questionable (c7 adfvn) and suggesting the LTH are born from Bad trades, or the share price might dip below 12p because that what shares do (Ivy) .... is not a prescription for a share rise based on fundamentals. So unless you want to be clued to the screen and become a mini trader ... its not realistic at all. However having a great understanding of the fundamentals gives the buyer the safety net of true value if the market moves in directions that make some uncomfortable, because the worse thing to do is chase a loss and on a share that can explode in value on a deal miss out on that gain because of 1p movements. Buy and Hold gives you that comfort. then its all about the number you hold when the news breaks. Just because they have not announced a deal, they still come out of the blue, Glycans is not priced in ... if it is we have just raised funds sub 10p on moditope and immunobody because value has to be attributed to that RNS SCIB1 ....Fantastic phase 1/2 plus double dose at 8mg trials run in adjuvant Melanoma 5 year proof of cancer patient survival no toxicity SCIB1 combo about to start all the evidence from other combo trials points to successful synergy with keytruda, and Scancells own data in mice is a significant increase in efficacy of both products compared to using as a mono therapy and of course no added toxicity SCIB2 taken up by CRUK with the potential to increase to 4 targets at minimal cost to Scancell Modi1 in manufacture 4 targets 100% success in mice, and Memory response to re-challenge Modi2 defined 4 targets Modi3 could be completely supported by the Grand Challenge with a 20m grant going after the hardest to treat cancers Moditope TCR collaboration with BioNtech with a commercial outcome at the end or sooner. other immunobodies in development Glycan Platform now added to the IP could be used to boost inflammation on cold cancers .. and run complimentary to immunobody and moditope, again potentially increasing efficacy (making it difficult for other products to prove against scancell superiority) Other "stress induced" PTM has been identified, as yet full details unknown. (moditope is a PTM) �11m in the bank sufficient to complete SCIB1 trials and initiate Modi1 trials. Moditope 37 epitopes discovered to induce an immune response (modi1 uses 3) Potential to treat every cancer (not sure on blood cancers) This reads like the oncology pipeline of a Major Pharma MCAP 45m

Roche 15,000 staff at Genentech BioNtech 150 .. Scancell 15 lol ..... with the IP to lead them in the Grand Challenge who is better at this game ? Maybe we buy Roche ? LOL problem then in doing a deal with us is sorted

, BioNtech does not have the capital or size to handle Scancell pipeline, it would have to be Roche. BioNtech itself has had to do deals with Roche. Scancell pipeline now is as big if not bigger than most majors. only the market just does not get it.

"""to enable the modification of the constant region (FC) of a human antibody to allow direct tumour killing""" The FC region on Immunobody targets the Dendritic system to activate the immune response ...... let you have a think about that one ........ a Direct Killing machine ...

BioNtech system only seeks T cells that go active against specific Epitopes, in this case 3 modi1 and the deal will be based around those 3. If that is successful, then that gives you an indication of the value in the remaining epitopes, but only value is TCR . this does not value the Epitopes full potential, as that occurs when we see clinical results from the phase1/2 modi1 trial.

Patents being written for new modification Yep read it .. as you say strong stuff .. Pancreatic 74% that is a very big number

Yes Boom ... so we agreed then 4 platforms ?

4 Platforms .... Tick tock

But its important that the tech guys have some sort of idea how this all fits together , we don't want to promote another PTM that does not exist ... but as i see it, there could be one or two still in play ... because the 2017 AGM mentions then as NEW patents being written ...... Patents being written for new modification  Patents being written for new combinations https://www.scancell.co.uk/file-manager/PDFs/agm-presentation-2017.pdf page 12

LOL .. but i have already said that many times, that we should wait and see what other PTM are in the pipeline because many have been mentioned, it was your link that prompted me ... hang on "SIPTM" .... Many proteins can be citrullinated  Adenylcyclase associated protein, α-enolase, aggregan, albumin, aldolase, anti-thrombin, asporin, β-actin, B23, BiP, calreticulin, capping protein α-1 subunit, cartilage intermediate layer protein, cathepsin D, co-activator complex, collagen, elongation factor 1α, F-actin, far upstream elementbinding proteins 1 and 2, fibrinogen, filaggrin, glucose regulated protein, heparin binding protein, histamine receptor, histone, HSP60, HSP90, mitochondrial aldehyde dehydrogenase, nucleophosmin, phosphoglycerate kinase 1, protein disulphide-isomerase ER60 precursor, vimentin  Any of these could be targets for incorporation into Moditope� immunotherapies  Other post-translational modifications also occur  Nitration of tyrosine  Oxidation of tryptophan  Demination of glutamine or asparagine  Many such modified amino acids have been found within MHC-bound peptides, indicating they may also be targets for immunotherapy If we go back to the 2013 Investor day .. the only mention of sugars is "glucose regulated protein" but that is based on citrullination not glycosylation so the current moditope patent i dont think even mentions it ... anyway its a platform that we have now ... Just interesting to try and cross ref ...